BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Institute of Biomedical Engineering (BME) - ECPv6.17.4.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Institute of Biomedical Engineering (BME)
X-ORIGINAL-URL:https://bme.utoronto.ca
X-WR-CALDESC:Events for Institute of Biomedical Engineering (BME)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220621T110000
DTEND;TZID=America/Toronto:20220621T120000
DTSTAMP:20220603T151630Z
CREATED:20220603T151630Z
LAST-MODIFIED:20220603T151630Z
UID:10000028-1655809200-1655812800@bme.utoronto.ca
SUMMARY:Insights from the Endotronix Journey: A PMA Medtech “Startup" Story
DESCRIPTION:Please join us for an ECHO webinar on Tuesday June 21\, 2022 (11 am – 12 pm EST) featuring Dr. Harry Rowland (CEO and Co-founder\, Endotronix). Dr. Rowland’s presentation entitled\, “Insights from the Endotronix Journey: A PMA Medtech “Startup” Story”\, will feature an overview of Endotronix\, its technologies and the story behind its success. Endotronix is a medical technology company\, delivering an integrated platform that provides comprehensive\, reimbursable health management innovations for patients suffering from advanced heart failure. Please see attachment for more details. \n\nRegister in advance for this webinar: https://us02web.zoom.us/meeting/register/tZwkc-GrqD0sGtcnluN7KLI2wNtAxZ1kYIx9 \nAfter registering\, you will receive a confirmation email containing information about joining the webinar. \n  \nECHO is an entrepreneurship training program\, funded and organized in a partnership between (i) the Translational Biology and Engineering Program (TBEP)\, the University of Toronto component of the Ted Rogers Centre for Heart Research\, and (ii) the Health Innovation Hub (H2i).
URL:https://bme.utoronto.ca/event/insights-from-the-endotronix-journey-a-pma-medtech-startup-story/
CATEGORIES:External Speaker Series
ORGANIZER;CN="Translational Biology and Engineering Program (TBEP)":MAILTO:reception.tbep@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220621T120000
DTEND;TZID=America/Toronto:20220621T130000
DTSTAMP:20220621T153842Z
CREATED:20220520T150058Z
LAST-MODIFIED:20220621T153842Z
UID:10000024-1655812800-1655816400@bme.utoronto.ca
SUMMARY:Global Speaker Series: Gilbert Bernier\, PhD - Université de Montréal
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians.\nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Gilbert Bernier\, PhD\, Associate Professor in the Department of Neuroscience at Université de Montréal.\nThe title of this talk will be\, “Cone photoreceptor sheet transplantation for the treatment of macular degenerations”\nRegister now\nHybrid event\, with in-person and virtual options\nIn-person will be held at the Terrence Donnelly Centre for Cellular & Biomolecular Research\, Red Room.\nVirtual event links will be sent after registration. \nMore About Gilbert bernier:\nProfessor Gilbert Bernier performed is graduated studies in Molecular Biology at Montreal University where he characterized the gene mutated in the mouse neurological disorder dystonia musculorum. In 1997\, he moved to the Max-Planck Institute of Biophysical Chemistry in Germany to study developmental biology of the retina. Since 2001\, he is heading the laboratory of stem cell and developmental biology at Maisonneuve-Rosemont Hospital to exploit the potential of human pluripotent stem cells for the study and treatment of neurodegenerative diseases such as retinal degenerative diseases and Alzheimer’s disease. Professor Bernier has also contributed to the characterization of Polycomb group proteins function in brain cancer\, DNA repair\, and premature ageing. He is Professor at the Neuroscience Department of Montreal University since 2012. He is co-founder and CEO of StemAxonTM\, a Canadian corporation involved in the development of new treatments for neurodegenerative diseases.\n Learn more about Gilbert Bernier
URL:https://bme.utoronto.ca/event/global-speaker-series-gilbert-bernier-phd-universite-de-montreal/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:External Speaker Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220623T130000
DTEND;TZID=America/Toronto:20220623T140000
DTSTAMP:20220609T150225Z
CREATED:20220609T144131Z
LAST-MODIFIED:20220609T150225Z
UID:10000001-1655989200-1655992800@bme.utoronto.ca
SUMMARY:Faculty Search Candidate: Designer polymer excipients to enable next-generation insulin formulations
DESCRIPTION:Caitlin Maikawa\, PhD\nAbstract: Insulin was first isolated a century ago\, yet commercial formulations of insulin for hormone replacement therapy fall short of mimicking the endogenous glycemic control that occurs in non-diabetic individuals. Moreover\, diabetes management is increasingly relying on automated insulin delivery using closed-loop systems to improve glucose management and reduce patient burden. However\, improvements in insulin formulations\, sensors\, and algorithms are required to shift from hybrid systems to fully autonomous delivery. Insulin formulations that better mimic secretion from the beta-cells\, by enabling more rapid insulin absorption kinetics and/or co-delivering complementary hormones (i.e. amylin)\, would improve diabetes management. However\, formulation innovation is complicated by the poor stability of insulin monomers and amylin. Here\, I will discuss two polymeric excipient platforms (non-covalent PEGylation and amphiphilic copolymer excipients) that can be used to increase the stability of insulin in formulation and modulate insulin pharmacokinetics. Using these designer excipients\, I have developed three insulin formulations: (i) an ultrafast monomeric insulin lispro\, (ii) an insulin-amylin co-formulation and (iii) an ultrafast co-formulation. These enhanced insulin formulations are promising candidates to address formulation challenges related to achieving fully autonomous insulin delivery\, improve glucose control\, and reduce the burden of treatment management for patients with diabetes.
URL:https://bme.utoronto.ca/event/designer-polymer-excipients-to-enable-next-generation-insulin-formulations/
LOCATION:MS2172
CATEGORIES:BME Faculty Search
END:VEVENT
END:VCALENDAR